BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Tyrosine kinase inhibitors (TKIs) like imatinib are standard treatment for chronic myeloid leukemia (CML).
• Drug resistance in CML is often caused by point mutations in the BCR-ABL kinase domain.
• Mutations outside the kinase domain (regulatory domains) may also contribute to TKI resistance by altering enzyme activity.

Purpose of the Study:

• To investigate the frequency and clinical relevance of BCR-ABL regulatory domain mutations in CML patients treated with imatinib.
• To determine if these mutations contribute to imatinib resistance and affect patient outcomes.

Main Methods:

• Screening of a cohort of 98 CML patients for mutations in BCR-ABL regulatory domains.
• In vitro functional assays to assess the impact of identified mutations on kinase activity and drug sensitivity.
• Correlation of mutation status with clinical response and relapse.

Main Results:

• Regulatory domain mutations were found in 7% (7/98) of patients, compared to 30% (29/98) with kinase domain mutations.
• One patient with a T212R regulatory domain mutation showed in vitro resistance to TKIs and relapsed.
• Most other regulatory domain mutations did not significantly impact drug sensitivity or kinase activity.

Conclusions:

• BCR-ABL regulatory domain mutations are infrequent in CML patients treated with imatinib.
• While uncommon, these mutations can confer drug resistance and may explain treatment failure in some patients lacking kinase domain mutations.
• The T212R mutation highlights the potential role of regulatory domain alterations in CML treatment resistance.